Geneoscopy
PrivateLast Round
Series C
Jan 8, 2025
Total Funding Raised
$218.35M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Geneoscopy operates in Healthcare & Life Sciences and is based in Saint Louis, Michigan. Its latest recorded funding round was a Series C round in January 2025.
Geneoscopy is a life sciences company that develops noninvasive diagnostic tests for gastrointestinal health, including colorectal cancer screening.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Devices
Business Model
B2B2C
Customer Profile
Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Geneoscopy Comparables
Compare Geneoscopy with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CellMax Life | 83% | |
| Quantum Cyber N.V. | 82% | |
| Universal Diagnostics | 82% |
For institutional investors. Book with your work email.
Geneoscopy Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 8, 2025 | ||||
| Debt | Nov 16, 2021 | ||||
| Series B | Nov 16, 2021 | ||||
| Series A | Oct 2, 2019 | ||||
| Seed | Apr 1, 2018 | ||||
Grant | Oct 23, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Geneoscopy Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovatus Capital Partners | Debt, Series B |
| NT Investments | Debt, Series C, Series B, Series A |
| Petrichor Healthcare Capital Management | Series C |
| Granger Management | Series C |
| Arch Grants | Grant, Seed |
| NT Investment Group | Series C |
| Cultivation Capital | Debt, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 64% MoM, reaching 4.1K.
- Jul 27, 2026
Grew 18% QoQ, from 61 to 72 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 20, 2026
Geneoscopy, Inc. launches ColoSense NextStep, a provider-enabled, opt-in navigation program that helps patients with positive ColoSense colorectal cancer screening results move toward a recommended follow-up colonoscopy in Missouri on Oct 20th '26.
For institutional investors. Book with your work email.
Geneoscopy Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Geneoscopy's valuation, stock price, and market status.
Is Geneoscopy a public or private company?
Geneoscopy is a private company.
What is the current stock price of Geneoscopy?
Geneoscopy is a private company, so its shares have no public market price. Caplight tracks Geneoscopy's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Geneoscopy worth (valuation)?
Valuation information for Geneoscopy is not publicly available.
Can I buy Geneoscopy stock?
Geneoscopy shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Geneoscopy's last funding round?
Geneoscopy's most recent funding round was Series C on January 8, 2025.
Who are the main investors in Geneoscopy?
Key investors in Geneoscopy include NT Investments, Cultivation Capital, LightChain Capital.
Will Geneoscopy IPO soon?
No public IPO plans have been announced for Geneoscopy.
How can I track Geneoscopy secondary market activity?
Caplight tracks bids, offers, and trades in Geneoscopy's shares on secondary markets.